Evidence on the therapeutic efficacy of mTOR inhibition in recurrent cervical cancer patients is limited but appears to have the potential to temporarily halt disease progression, even in heavily pretreated stages, while inducing only mild to moderate side effects. This evidence concerns the gene MTOR and cervical carcinoma.